Moreover, treatment by targeting both EGFR and STAT3 was demonstrated to play an important role in EGFR–STAT3 feedback loop blockade and restriction of pancreatic cancer volume.77 This evidence concerns the gene STAT3 and familial pancreatic carcinoma.